” When the Hexapro vaccine is delivered through HD-MAP applicator– instead of a needle– it produces better and quicker immune responses,” Dr. Muller stated.
” It likewise neutralizes numerous versions, including the UK and South Africa variants.
” And its much more user-friendly than a needle– you just click an applicator on the skin, and 5000 microscopic projections almost-imperceptibly deliver vaccine into the skin.”
UQs Dr. David Muller holding HD-MAP technology. Credit: The University of Queensland
Dr. Muller said the UQ group, together with Vaxxas, hoped to take the technology to the world and are searching for moneying opportunities to accelerate to scientific trials as quickly as possible.”
” Hexapro, provided by the high-density microarray patch, might significantly assist international vaccine rollout effort, particularly for billions of vulnerable individuals in low- and middle-income nations.
” Weve revealed this vaccine, when dry-coated on a spot, is stable for a minimum of 30 days at 25 degrees Celsius and one week at 40 degrees, so it does not have the cold chain requirements of some of the present choices.”
President and CEO of Vaxxas, David L. Hoey, stated he was exceptionally excited about the findings.
The UQ research study group, featuring (foreground, L-R) Dr. Chris McMillan, Dr. David Muller, (background, L-R) Dr. Alberto Amarilla, Dr. Naphak Modhiran Ortiz, and Ms. Jovin Choo. Credit: The University of Queensland
” These results are extremely clear– vaccination by HD-MAP produces much more powerful and more protective immune actions versus COVID-19 in model systems than by means of needle or syringe,” he said.
” We thank and acknowledge our extraordinary research study partners at UQ for these essential findings.
” The possibility of having a single-dose vaccine, that might be quickly dispersed and self-administered, would greatly enhance global pandemic vaccination abilities.”
Reference: 29 October 2021, Science Advances.DOI: 10.1126/ sciadv.abj8065.
Technicians dealing with the high-density microarray patch in the Vaxxas cleanroom. Credit: Vaxxas
A needle-free COVID-19 vaccination might be possible, with University of Queensland researchers effectively safeguarding mice from the infection by administering a US-developed vaccine candidate with a patch.
The University of Texas Hexapro vaccine candidate– delivered via the UQ-developed and Vaxxas-commercialized high-density microarray spot (HD-MAP)– provided protection versus COVID-19 disease with a single, pain-free click from a pocket-sized applicator.
High-density microarray patch technology. Credit: The University of Queensland
Dr. David Muller, from UQs School of Chemistry and Molecular Biosciences, stated the vaccine spot produced strong immune actions that were shown to be reliable when the mice were exposed to SARS-CoV-2– the infection that triggers COVID-19.
